Glivec Supreme Court hearing commences in India
This article was originally published in Scrip
Executive Summary
The Supreme Court of India has commenced hearing final arguments in the crucial patent case concerning Novartis anticancer compound, Glivec (imatinib mesylate), and its rejection due tocontravention of the controversial Section 3(d)provision in India's patent law.